← Leaderboards

Paul Vanveldhuisen

The Emmes Company, Llc

Google Scholar ↗PubMed ↗ORCID ↗

$63,018,753

Attributed

$63,018,753

Total exposure

3

Grants

3

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $14.2M · FY2011–22

$20M$15M$10M$5M$0

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

Funding mix

By agency

NIH$63,018,753 · 3

By mechanism

N01$63,018,753 · 3

Top collaborators

No co-investigators on record.

Most similar at The Emmes Company, Llc

Same institution · by research overlap

Jennifer McCormack$25,403,412
Eve Jelstrom$42,013,348
Traci E Clemons$15,192,293
Kathryn Hefner$7,088,164
Donald Stablein$6,357,875

Others in their field

Top investigators on “National Institute Of Drug Abuse”

Barbara Driver · Westat, Inc.$95,724,261
Jeffrey H Samet · Boston University Medical Campus$90,210,613
T John Winhusen · University Of Cincinnati$75,983,072
Lloyd D Johnston · University Of Michigan At Ann Arbor$60,310,192
Robert Lindblad · The Emmes Company, Llc$49,324,035
Richard A Miech · Johns Hopkins University$46,450,970

Research focus

National Institute Of Drug AbuseSiteStatisticsDrug AbuseClinical ResearchScienceBaseClinical TrialsFlexibilityQuality ControlReportingClinicData CollectionServicesProtocols DocumentationOnline SystemsStructureFamiliarityDesignInformation SystemsLeadershipData ManagementSubstance Abuse ProblemUrsidae Family

Grant awards (41)

OPTIMIZING RETENTION, DURATION&DISCONTINUATION STRATEGIES FOR OPIOID USE DISORDER PHARMACOTHERAPY (CTN-0100). 03/01/2020 - 08/15/2022. N01DA-19-2250.T$1,350,572

N01 · FY2022 · DA · contact PI

EMERGENCY DEPARTMENT-INITIATED BUPRENORPHINE AND VALIDATION NETWORK TRIAL (CTN-0099). DSC5 CONTRACT. 09/20/2019 - 11/12/2022. N01DA-19-2250.$490,336

N01 · FY2022 · DA · contact PI

SUBTHRESHOLD OPIOID USE DISORDER PREVENTION TRIAL (CTN-0101). DSC5 CONTRACT. 09/20/2019 - 11/16/2020. N01DA-19-2250.$245,168

N01 · FY2022 · DA · contact PI

ADOLESCENT SCREENING TO HELP ELIMINATE MISUSE (CTN-0060-A-1). 8/1/2020 - 12/31/2021. N01DA-19-2250. TASK ORDER 75N95020F00003 (TO14).$15,006

N01 · FY2022 · DA · contact PI

DSC MANAGEMENT AND SUPPORT FOR HELPING TO END ADDICTION LONG-TERM INITIATIVE (HEAL). 9/1/2021-8/31/2022. N01DA-19-2250. TASK ORDER 75N95021F00005 (TO2$2,432,878

N01 · FY2021 · DA · contact PI

LONGITUDINAL FOLLOW-UP OF INDIVIDUALS WITH OPIOID USE DISORDER (LFU-OUD). 09/01/2021 - 08/31/2026. N01DA-19-2250. TASK ORDER 75N95021F00007 (TO26).$1,847,761

N01 · FY2021 · DA · contact PI

Randomized, double-blind, placebo-controlled trial of monthly injectable buprenorphine for methamphetamine use disorder (MURB) (CTN-0110)$1,406,983

N01 · FY2021 · DA · contact PI

Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) (CTN-0109)$1,154,351

N01 · FY2021 · DA · contact PI

NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER MANAGEMENT AND SUPPORT. 03/01/2021 - 02/28/2022. N01DA-19-2250. TASK ORDER 75N95021F00001 (TO$1,090,680

N01 · FY2021 · DA · contact PI

PHARMACIST-INTEGRATED MODEL OF MEDICATION TREATMENT FOR OPIOID USE DISORDER (CTN-0116). 09/01/2021 - 03/01/2024. N01DA-19-2250. TASK ORDER 75N95021F00$686,833

N01 · FY2021 · DA · contact PI

NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER MANAGEMENT AND SUPPORT. 03/01/2020 - 02/28/2021. N01DA-19-2250. TASK ORDER 75N95020F00001 (TO$549,285

N01 · FY2021 · DA · contact PI

SUBTHRESHOLD OPIOID USE DISORDER PREVENTION TRIAL (CTN-0101). DSC5 CONTRACT. 09/20/2019 - 11/16/2020. N01DA-19-2250.$245,168

N01 · FY2021 · DA · contact PI

DSC MANAGEMENT AND SUPPORT FOR HELPING TO END ADDICTION LONG-TERM INITIATIVE (HEAL). 9/21/2020-9/20/2021. N01DA-19-2250. TASK ORDER 75N95020F00008 (TO$183,095

N01 · FY2021 · DA · contact PI

NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER MANAGEMENT AND SUPPORT. 03/01/2020 - 02/28/2021. N01DA-19-2250. TASK ORDER 75N95020F00001 (TO$2,113,098

N01 · FY2020 · DA · contact PI

OPTIMIZING RETENTION, DURATION&DISCONTINUATION STRATEGIES FOR OPIOID USE DISORDER PHARMACOTHERAPY (CTN-0100). 03/01/2020 - 08/15/2022. N01DA-19-2250.T$1,772,024

N01 · FY2020 · DA · contact PI

DSC MANAGEMENT AND SUPPORT FOR HELPING TO END ADDICTION LONG-TERM INITIATIVE (HEAL). 9/21/2020-9/20/2021. N01DA-19-2250. TASK ORDER 75N95020F00008 (TO$1,104,229

N01 · FY2020 · DA · contact PI

TRANSCRANIAL MAGNETIC STIMULATION FOR THE TREATMENT OF METHAMPHETAMINE/COCAINE USE DISORDER (CTN-0108). 9/21/2020-7/17/2023. N01DA-19-2250. TASK ORDER$830,919

N01 · FY2020 · DA · contact PI

PEER INTERVENTION TO LINK OVERDOSE SURVIVORS TO TREATMENT (CTN-0107). 9/1/2020-7/3/2023. N01DA-19-2250. TASK ORDER 75N95020F00006 (TO17).$799,951

N01 · FY2020 · DA · contact PI

SUBTHRESHOLD OPIOID USE DISORDER PREVENTION TRIAL (CTN-0101). DSC5 CONTRACT. 09/20/2019 - 11/16/2020. N01DA-19-2250.$743,886

N01 · FY2020 · DA · contact PI

INTEGRATING PHARMACY-BASED PREVENTION&TREATMENT OF OPIOID&OTHER SUBSTANCE USE DISORDERS: A SURVEY OF PHARMACISTS&STAKEHOLDERS. 9/1/2020-7/31/2022. N01$350,016

N01 · FY2020 · DA · contact PI

ANCILLARY STUDY OF THE ADOPTION AND SUSTAINABILITY OF ED-INITIATED BUPRENORPHINE (CTN-0079-A-1). DSC5 CONTRACT. 09/20/2019 - 02/28/2021. N01DA-19-2250.$237,062

N01 · FY2020 · DA · contact PI

PRIMARY CARE OPIOID USE DISORDERS TREATMENT TRIAL (CTN-0074). 9/1/2020 - 12/31/2021. N01DA-19-2250. TASK ORDER 75N95020F00004 (TO15).$236,371

N01 · FY2020 · DA · contact PI

ADOLESCENT SCREENING TO HELP ELIMINATE MISUSE (CTN-0060-A-1). 8/1/2020 - 12/31/2021. N01DA-19-2250. TASK ORDER 75N95020F00003 (TO14).$185,108

N01 · FY2020 · DA · contact PI

DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT FOR NIDA (DSC4).$4,085,691

N01 · FY2019 · DA · contact PI

EXEMPLAR HOSPITAL INITIATION TRIAL TO ENHANCE TREATMENT ENGAGEMENT (CTN-0098). DSC5 CONTRACT. 09/20/2019 - 06/01/2024. N01DA-19-2250.$2,030,956

N01 · FY2019 · DA · contact PI

EMERGENCY DEPARTMENT-INITIATED BUPRENORPHINE AND VALIDATION NETWORK TRIAL (CTN-0099). DSC5 CONTRACT. 09/20/2019 - 11/12/2022. N01DA-19-2250.$1,661,684

N01 · FY2019 · DA · contact PI

RURAL EXPANSION OF MEDICATIONS FOR OPIOID USE DISORDER (CTN-0102). DSC5 CONTRACT. 09/20/2019 - 05/15/2023. N01DA-19-2250.$1,614,088

N01 · FY2019 · DA · contact PI

SURMOUNTING WITHDRAWAL TO INITIATE FAST TREATMENT WITH NALTREXONE (CTN-0097). DSC5 CONTRACT. 09/20/2019 - 11/23/2021. N01DA-19-2250.$1,251,569

N01 · FY2019 · DA · contact PI

NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER. 09/01/2019 - 02/29/2020. N01DA-19-2250. TASK ORDER NO 01.$957,870

N01 · FY2019 · DA · contact PI

CLINIC-RANDOMIZED TRIAL OF CLINICAL DECISION SUPPORT FOR OPIOID USE DISORDERS IN MEDICAL SETTINGS (CTN-0095). DSC5 CONTRACT. 09/20/2019 - 06/28/2024. N01DA-19-2250.$881,366

N01 · FY2019 · DA · contact PI

SUBTHRESHOLD OPIOID USE DISORDER PREVENTION TRIAL (CTN-0101). DSC5 CONTRACT. 09/20/2019 - 11/16/2020. N01DA-19-2250.$649,944

N01 · FY2019 · DA · contact PI

ANCILLARY STUDY OF THE ADOPTION AND SUSTAINABILITY OF ED-INITIATED BUPRENORPHINE (CTN-0079-A-1). DSC5 CONTRACT. 09/20/2019 - 02/28/2021. N01DA-19-2250.$552,523

N01 · FY2019 · DA · contact PI

CULTURALLY CENTERED TREATMENT FOR OUD IMPLEMENTATION FOR ADDICTION TREATMENT PROGRAMS SERVING AMERICAN INDIAN/ALASKA NATIVES (CTN-0096). DSC5 CONTRACT. 09/20/2019 - 11/15/2022. N01DA-19-2250.$511,983

N01 · FY2019 · DA · contact PI

IGF::OT::IGF: DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT FOR NIDA (DSC4). N01DA-14-2237. PERIOD OF PERFORMANCE: JUNE 19, 2014 TO JUNE 18, 2019.$3,219,557

N01 · FY2018 · DA · contact PI

IGF::OT::IGF: DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT FOR NIDA (DSC4). N01DA-14-2237. PERIOD OF PERFORMANCE: JUNE 19, 2014 TO JUNE 18, 2019.$3,733,019

N01 · FY2017 · DA · contact PI

IGF::OT::IGF: DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT FOR NIDA (DSC4). N01DA-14-2237. PERIOD OF PERFORMANCE: JUNE 19, 2014 TO JUNE 18, 2019.$3,582,979

N01 · FY2016 · DA · contact PI

IGF::OT::IGF: DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT FOR NIDA (DSC4). N01DA-14-2237. PERIOD OF PERFORMANCE: JUNE 19, 2014 TO JUNE 18, 2019.$3,499,899

N01 · FY2015 · DA · contact PI

IGF::OT::IGF: DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT FOR NIDA (DSC4). N01DA-14-2237. PERIOD OF PERFORMANCE: JUNE 19, 2014 TO JUNE 18, 2019.$3,378,726

N01 · FY2014 · DA · contact PI

DATA AND STATISTICS CENTER FOR THE NIDA CLINICAL TRIALS NETWORK$3,368,894

N01 · FY2013 · DA · contact PI

DATA AND STATISTICS CENTER FOR THE NIDA CLINICAL TRIALS NETWORK$3,956,081

N01 · FY2012 · DA · contact PI

DATA AND STATISTICS CENTER FOR THE NIDA CLINICAL TRIALS NETWORK$4,011,144

N01 · FY2011 · DA · contact PI